Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
Open Access
- 1 February 2014
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 7, 187-192
Abstract
Advanced pancreatic adenocarcinoma is a deadly disease and is considered incurable. For the past two decades, gemcitabine remained the major chemotherapeutic drug with modest clinical benefit. Many chemotherapy and targeted agents were combined with gemcitabine but failed to demonstrate improvement in pancreatic cancer (PC) survival. Taxanes (paclitaxel, docetaxel) were introduced in the clinic as anti-microtubule agents and showed activity against PC cells in vitro; however, clinical efficacy was limited. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer. Recently, nab-paclitaxel was tested in a large Phase III clinical trial in combination with gemcitabine for the treatment of advanced PC. The data showed that the addition of nab-paclitaxel improved the response rate (7% in gemcitabine alone versus 23% in combination), progression-free survival (from 3.7 months to 5.5 months), and overall survival from 6.7 months to 8.5 months, compared to single agent gemcitabine. Through this review, we provide the preclinical and clinical progress in the development of nab-paclitaxel for the treatment of metastatic PC.Keywords
This publication has 44 references indexed in Scilit:
- SPARC independent drug delivery and antitumour effects of nab -paclitaxel in genetically engineered miceGut, 2013
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancerBritish Journal of Cancer, 2013
- Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancerCancer Chemotherapy and Pharmacology, 2013
- nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic CancerCancer Discovery, 2012
- Advances in Pancreatic Cancer Detection2010
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerJournal of Clinical Oncology, 2005
- γ-Linolenic acid regulates the expression and secretion of SPARC in human cancer cellsProstaglandins, Leukotrienes and Essential Fatty Acids, 2005
- Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II StudyJournal of Clinical Oncology, 1999
- Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative studyBritish Journal of Cancer, 1999
- Hypersensitivity reactions from taxol.Journal of Clinical Oncology, 1990